Design of isatin-based anticancer agents targeting CDK2, with the identification of a dual CDK1/2 inhibitory lead: a study bridging synthesis, biological profiling, and in silico exploration.
- DOI
- 10.1039/d6md00738d
- Published
- 2026 Nov 6
- Container
- RSC medicinal chemistry
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1039/d6md00738d,
title = {Design of isatin-based anticancer agents targeting CDK2, with the identification of a dual CDK1/2 inhibitory lead: a study bridging synthesis, biological profiling, and in silico exploration.},
author = {Meky MZH and Mohammed ER and El-Zoheiry HH and Hanafy NS and Abou-Seri SM},
year = {2026},
journal = {RSC medicinal chemistry},
doi = {10.1039/d6md00738d},
url = {https://doi.org/10.1039/d6md00738d}
}RIS
TY - JOUR TI - Design of isatin-based anticancer agents targeting CDK2, with the identification of a dual CDK1/2 inhibitory lead: a study bridging synthesis, biological profiling, and in silico exploration. AU - Meky MZH AU - Mohammed ER AU - El-Zoheiry HH AU - Hanafy NS AU - Abou-Seri SM PY - 2026 JO - RSC medicinal chemistry DO - 10.1039/d6md00738d UR - https://doi.org/10.1039/d6md00738d ER -
APA
MZH, M., ER, M., HH, E., NS, H., & SM, A. (2026). Design of isatin-based anticancer agents targeting CDK2, with the identification of a dual CDK1/2 inhibitory lead: a study bridging synthesis, biological profiling, and in silico exploration.. RSC medicinal chemistry. https://doi.org/10.1039/d6md00738d
Source records
- pubmed · retrieved 2026-11-10T09:13:57.627Z